Interestingly, this poorly immunogenic murine HNSCC line has shown response to therapeutic inhibitors of mTOR but not PD-L1, though neither treatment increased infiltration of CD8+ TILs [56]. The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.